Functional p53 is required for rapid restoration of daunorubicin-induced lesions of the spleen

BMC Cancer

Lars Herfindal³  Lene Myhren²  Bjørn Tore Gjertsen¹  Stein Ove Døskeland²  Gro Gausdal² 

[1] Institute of Medicine, Hematology Section, University of Bergen, PO Box 7804, 5020, Bergen, Norway

[2] Department of Biomedicine, University of Bergen, Jonas Lies vei 91, 5009, Bergen, Norway

[3] Translational Signalling Group, Haukeland University Hospital, Jonas Lies vei 91, 5009, Bergen, Norway

关键词: Apoptosis;    Lipofuscin;    Daunorubicin;    p63;    p53;    Spleen;   

Others  :  1079649
DOI  :  10.1186/1471-2407-13-341

 received in 2013-02-27, accepted in 2013-07-08,  发布年份 2013

【 摘 要 】

Background

The tumour suppressor and transcription factor p53 is a major determinant of the therapeutic response to anthracyclines. In healthy tissue, p53 is also considered pivotal for side effects of anthracycline treatment such as lesions in haematopoietic tissues like the spleen. We used a Trp53null mouse to explore the significance of p53 in anthracycline (daunorubicin) induced lesions in the spleen.

Methods

Mice with wild type or deleted Trp53 were treated with the daunorubicin (DNR) for three consecutive days. Spleens were collected at various time points after treatment, and examined for signs of chemotherapy-related lesions by microscopic analysis of haematoxylin-eosin or tunel-stained paraffin sections. Expression of death-inducing proteins was analysed by immunoblotting. Changes between Trp53 wild type and null mice were compared by t-tests.

Results

Signs of cell death (pyknotic nuclei and tunel-positive cells) in the white pulp of the spleen occurred earlier following DNR exposure in wt-mice compared to Trp53-null mice. While the spleen of wt-mice recovered to normal morphology, the spleen of the Trp53-null animals still had lesions with large necrotic areas and disorganised histologic appearance eight days after treatment. Immunoblotting showed that only Trp53-wt mice had significant increase in p21 after DNR treatment. However, both wt and null mice had elevated p63 levels following DNR exposure.

Conclusions

p53 protects against severe and enduring cellular damage of the spleen parenchyma after DNR treatment, and initial DNR-induced apoptosis is not predictive of tissue lesions in the spleen. Our data indicate that p53 induction following DNR treatment serves to protect rather than to destroy normal tissue.

【 授权许可】

   
2013 Herfindal et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

【 参考文献 】

• [1]Wattel E, Preudhomme C, Hecquet B, Vanrumbeke M, Quesnel B, Dervite I, Morel P, Fenaux P: p53 mutations are associated with resistance to chemotherapy and short survival in hematologic malignancies. Blood 1994, 84(9):3148-3157.
• [2]Peller S: Clinical implications of p53: effect on prognosis, tumor progression and chemotherapy response. Semin Cancer Biol 1998, 8(5):379-387.
• [3]McCubrey JA, Abrams SL, Ligresti G, Misaghian N, Wong EW, Steelman LS, Basecke J, Troppmair J, Libra M, Nicoletti F, et al.: Involvement of p53 and Raf/MEK/ERK pathways in hematopoietic drug resistance. Leukemia 2008, 22(11):2080-2090.
• [4]Rucker FG, Schlenk RF, Bullinger L, Kayser S, Teleanu V, Kett H, Habdank M, Kugler CM, Holzmann K, Gaidzik VI, et al.: TP53 alterations in acute myeloid leukemia with complex karyotype correlate with specific copy number alterations, monosomal karyotype, and dismal outcome. Blood 2012, 119(9):2114-2121.
• [5]Aas T, Borresen AL, Geisler S, Smith-Sorensen B, Johnsen H, Varhaug JE, Akslen LA, Lonning PE: Specific P53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients. Nat Med 1996, 2(7):811-814.
• [6]Weller M: Predicting response to cancer chemotherapy: the role of p53. Cell Tissue Res 1998, 292(3):435-445.
• [7]Kojima K, Konopleva M, Samudio IJ, Shikami M, Cabreira-Hansen M, McQueen T, Ruvolo V, Tsao T, Zeng Z, Vassilev LT, et al.: MDM2 antagonists induce p53-dependent apoptosis in AML: implications for leukemia therapy. Blood 2005, 106(9):3150-3159.
• [8]Peterson LF, Mitrikeska E, Giannola D, Lui Y, Sun H, Bixby D, Malek SN, Donato NJ, Wang S, Talpaz M: p53 stabilization induces apoptosis in chronic myeloid leukemia blast crisis cells. Leukemia 2011, 25(5):761-769.
• [9]McCormack E, Haaland I, Venas G, Forthun RB, Huseby S, Gausdal G, Knappskog S, Micklem DR, Lorens JB, Bruserud O, et al.: Synergistic induction of p53 mediated apoptosis by valproic acid and nutlin-3 in acute myeloid leukemia. Leukemia 2011, 26(5):910-917.
• [10]Yu X, Vazquez A, Levine AJ, Carpizo DR: Allele-specific p53 mutant reactivation. Cancer Cell 2012, 21(5):614-625.
• [11]Morandell S, Yaffe MB: Exploiting synthetic lethal interactions between DNA damage signaling, checkpoint control, and p53 for targeted cancer therapy. Prog Mol Biol Transl Sci 2012, 110:289-314.
• [12]Saha MN, Jiang H, Yang Y, Zhu X, Wang X, Schimmer AD, Qiu L, Chang H: Targeting p53 via JNK pathway: a novel role of RITA for apoptotic signaling in multiple myeloma. PLoS One 2012, 7(1):e30215.
• [13]Buc-Calderon P, Praet M, Ruysschaert JM, Roberfroid M: Increasing therapeutic effect and reducing toxicity of doxorubicin by N-acyl dehydroalanines. Eur J Cancer Clin Oncol 1989, 25(4):679-685.
• [14]Jacks T, Remington L, Williams BO, Schmitt EM, Halachmi S, Bronson RT, Weinberg RA: Tumor spectrum analysis in p53-mutant mice. Curr Biol 1994, 4(1):1-7.
• [15]Gausdal G, Gjertsen BT, Fladmark KE, Demol H, Vandekerckhove J, Doskeland SO: Caspase-dependent, geldanamycin-enhanced cleavage of co-chaperone p23 in leukemic apoptosis. Leukemia 2004, 18(12):1989-1996.
• [16]Mayer RJ, Davis RB, Schiffer CA, Berg DT, Powell BL, Schulman P, Omura GA, Moore JO, McIntyre OR, Frei E 3rd: Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B. N Engl J Med 1994, 331(14):896-903.
• [17]Komarova EA, Chernov MV, Franks R, Wang K, Armin G, Zelnick CR, Chin DM, Bacus SS, Stark GR, Gudkov AV: Transgenic mice with p53-responsive lacZ: p53 activity varies dramatically during normal development and determines radiation and drug sensitivity in vivo. EMBO J 1997, 16(6):1391-1400.
• [18]Wilhelm J, Brzak P, Rejholcova M: Changes of lipofuscin-like pigments in erythrocytes and spleen after whole-body gamma irradiation of rats. Radiat Res 1989, 120(2):227-233.
• [19]Crichton DN, Busuttil A, Price WH: Splenic lipofuscinosis in mice. J Pathol 1978, 126(2):113-120.
• [20]Goris H, Bungart B, Loeffler M, Schmitz S, Nijhof W: Migration of stem cells and progenitors between marrow and spleen following thiamphenicol treatment of mice. Exp Hematol 1990, 18(5):400-407.
• [21]Komarova EA, Kondratov RV, Wang K, Christov K, Golovkina TV, Goldblum JR, Gudkov AV: Dual effect of p53 on radiation sensitivity in vivo: p53 promotes hematopoietic injury, but protects from gastro-intestinal syndrome in mice. Oncogene 2004, 23(19):3265-3271.
• [22]Perez BA, Ghafoori AP, Lee CL, Johnston SM, Li Y, Moroshek JG, Ma Y, Mukherjee S, Kim Y, Badea CT, et al.: Assessing the radiation response of lung cancer with different gene mutations using genetically engineered mice. Front Oncol 2013, 3:72.
• [23]Yoshihara Y, Wu D, Kubo N, Sang M, Nakagawara A, Ozaki T: Inhibitory role of E2F-1 in the regulation of tumor suppressor p53 during DNA damage response. Biochem Biophys Res Commun 2012, 421(1):57-63.
• [24]Flores ER, Tsai KY, Crowley D, Sengupta S, Yang A, McKeon F, Jacks T: p63 and p73 are required for p53-dependent apoptosis in response to DNA damage. Nature 2002, 416(6880):560-564.
• [25]Gressner O, Schilling T, Lorenz K, Schulze Schleithoff E, Koch A, Schulze-Bergkamen H, Lena AM, Candi E, Terrinoni A, Catani MV, et al.: TAp63alpha induces apoptosis by activating signaling via death receptors and mitochondria. EMBO J 2005, 24(13):2458-2471.
• [26]Jackson JG, Pant V, Li Q, Chang LL, Quintas-Cardama A, Garza D, Tavana O, Yang P, Manshouri T, Li Y, et al.: p53-mediated senescence impairs the apoptotic response to chemotherapy and clinical outcome in breast cancer. Cancer Cell 2012, 21(6):793-806.
• [27]Bunz F, Hwang PM, Torrance C, Waldman T, Zhang Y, Dillehay L, Williams J, Lengauer C, Kinzler KW, Vogelstein B: Disruption of p53 in human cancer cells alters the responses to therapeutic agents. J Clin Invest 1999, 104(3):263-269.